MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
56.93
+1.03
+1.84%
After Hours: 56.93 0 0.00% 16:20 03/27 EDT
OPEN
55.86
PREV CLOSE
55.90
HIGH
57.07
LOW
54.69
VOLUME
628.67K
TURNOVER
0
52 WEEK HIGH
77.32
52 WEEK LOW
44.52
MARKET CAP
10.36B
P/E (TTM)
-19.3429
1D
5D
1M
3M
1Y
5Y
Aroundtown posts $2.64 bln annual loss amid German property crisis
NASDAQ · 1d ago
Aroundtown posts 2.43 billion euro loss amid German property crisis
NASDAQ · 1d ago
Weekly Report: what happened at LEGN last week (0318-0322)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)
Cowen analyst Yaron Werber maintains a Buy rating on Legend Biotech. The company's shares closed at $58.14 on March 11. 2 analysts have recently weighed in on AbbVie and Legend Bi biotech with bullish sentiments. The analysts have a combined 12-month target price of $86.55.
TipRanks · 4d ago
Legend Biotech files automatic mixed securities shelf
Seeking Alpha · 03/19 15:47
Legend Biotech Is Maintained at Buy by UBS
Dow Jones · 03/18 14:28
Legend Biotech Price Target Raised to $81.00/Share From $76.00 by UBS
Dow Jones · 03/18 14:28
UBS Maintains Buy on Legend Biotech, Raises Price Target to $81
Benzinga · 03/18 14:18
More
About LEGN
Legend Biotech Corporation is a global biotechnology company, which is focused on developing, manufacturing and commercializing novel therapies to treat life-threatening diseases. The Company is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a CAR-T cell therapy for the treatment of multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also developing an allogeneic gamma delta CAR-T product candidate targeting B-cell maturation antigen for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.